Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Phase I study of autologous transgenic T cells expressing high affinity mesothelin-specific T-cell receptor (TCR; FH-TCR TMSLN) in patients with metastatic pancreatic ductal adenocarcinoma (mPDA).
Authors
E. Gabriela Chiorean
University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA;
E. Gabriela Chiorean , Aude Chapuis , Andrew L. Coveler , Cecilia CS Yeung , Ted Gooley , David Bing Zhen , Gentry Teng King , Lindsay Marie Hannan , Stacey A. Cohen , Rachael A Safyan , Anthony Germani , Susan Ra , Jennifer Casserd , Thomas Schmitt , Philip D Greenberg
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT04809766
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr TPS779)
DOI
10.1200/JCO.2023.41.4_suppl.TPS779
Abstract #
TPS779
Poster Bd #
Q15
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Phase IIA study of high-affinity TCR-T (TAEST16001) targeting NY-ESO-1 in soft tissue sarcoma.
First Author: Jiayong Liu
Poster
2017 ASCO Annual Meeting
Two phase I/II open label clinical trials evaluating the safety and efficacy of autologous T cells expressing enhanced TCRs specific for NY-ESO-1 or MAGE-A10 in subjects with stage IIIb or stage IV non-small cell lung cancer (NCT02588612/NCT02592577).
First Author: Ben C. Creelan
Poster
2023 ASCO Annual Meeting
Phase I results of human endogenous retrovirus type-E (HERV-E) TCR transduced T-cells in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC).
First Author: Rosa Nadal
Poster
2023 ASCO Annual Meeting
Safety and efficacy of Sleeping Beauty TCR-T cells targeting shared KRAS and TP53 mutations expressed by solid tumors in first-in-human phase 1 study.
First Author: Maria Pia Morelli